Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Umbricht

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Biorxiv : the Preprint Server for Biology|May 7, 2026
Linking human brain functional connectivity to underlying neurotransmissionLeon D Lotter, Golia Shafiei, Daouia Larabi, et al.
Psychiatric Genetics|September 10, 2002
Genetic polymorphisms and cerebrospinal fluid levels of tissue inhibitor of metalloproteinases 1 in sporadic Alzheimer's diseaseM Axel Wollmer, Andreas Papassotiropoulos, Johannes R Streffer, et al.
Journal of Psychopharmacology (Oxford, England)|October 16, 2025
A novel psychedelic 5-HT<sub>2A</sub> receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteerGerard J Marek, Soma Makai-Bölöni, Daniel Umbricht, et al.
Neuroscience Applied|August 21, 2025
Using the grip strength effort task to measure reward processing dysfunction in schizophrenia and major depressive disorderAsad Malik, Shannon N Millard, Ailidh Finlayson, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
Scientific Reports|March 8, 2018
Cerebral blood flow predicts differential neurotransmitter activityJuergen Dukart, Štefan Holiga, Christopher Chatham, et al.
Schizophrenia Research|September 14, 2013
Issues and perspectives in designing clinical trials for negative symptoms in schizophreniaStephen R Marder, Larry Alphs, Ion-George Anghelescu, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Prasinezumab in Early-Stage Parkinson's DiseaseGennaro Pagano, Kirsten I Taylor, Judith Anzures-Cabrera, et al.
The American Journal of Psychiatry|December 7, 2016
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and TerminologyOliver D Howes, Rob McCutcheon, Ofer Agid, et al.
The American Journal of Psychiatry|October 8, 2025
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve ThemOliver D Howes, Bernard R Bukala, Eric Y H Chen, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Biorxiv : the Preprint Server for Biology|May 7, 2026
Linking human brain functional connectivity to underlying neurotransmissionLeon D Lotter, Golia Shafiei, Daouia Larabi, et al.
Psychiatric Genetics|September 10, 2002
Genetic polymorphisms and cerebrospinal fluid levels of tissue inhibitor of metalloproteinases 1 in sporadic Alzheimer's diseaseM Axel Wollmer, Andreas Papassotiropoulos, Johannes R Streffer, et al.
Journal of Psychopharmacology (Oxford, England)|October 16, 2025
A novel psychedelic 5-HT<sub>2A</sub> receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteerGerard J Marek, Soma Makai-Bölöni, Daniel Umbricht, et al.
Neuroscience Applied|August 21, 2025
Using the grip strength effort task to measure reward processing dysfunction in schizophrenia and major depressive disorderAsad Malik, Shannon N Millard, Ailidh Finlayson, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
Scientific Reports|March 8, 2018
Cerebral blood flow predicts differential neurotransmitter activityJuergen Dukart, Štefan Holiga, Christopher Chatham, et al.
Schizophrenia Research|September 14, 2013
Issues and perspectives in designing clinical trials for negative symptoms in schizophreniaStephen R Marder, Larry Alphs, Ion-George Anghelescu, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Prasinezumab in Early-Stage Parkinson's DiseaseGennaro Pagano, Kirsten I Taylor, Judith Anzures-Cabrera, et al.
The American Journal of Psychiatry|December 7, 2016
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and TerminologyOliver D Howes, Rob McCutcheon, Ofer Agid, et al.
The American Journal of Psychiatry|October 8, 2025
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve ThemOliver D Howes, Bernard R Bukala, Eric Y H Chen, et al.
Pageof 8